We appraised the methodology, execution and quality of the five published meta-analyses that are based on the five randomized controlled trials which compared cardiotocography (CTG)+ST analysis to cardiotocography. The meta-analyses contained errors, either created de novo in handling of original data or from a failure to recognize essential differences among the randomized controlled trials, particularly in their inclusion criteria and outcome parameters. No meta-analysis contained complete and relevant data from all five randomized controlled trials. We believe that one randomized controlled trial excluded in two of the meta-analyses should have been included, whereas one randomized controlled trial that was included in all meta-analyses, should have been excluded. After correction of the uncovered errors and exclusion of the randomized controlled trial that we deemed inappropriate, our new metaanalysis showed that CTG+ST monitoring significantly reduces the fetal scalp blood sampling usage (risk ratio 0.64; 95% confidence interval 0.47-0.88), total operative delivery rate (0.93; 0.88-0.99) and metabolic acidosis rate (0.61; 0.41-0.91).
Introduction
From 2012 to 2013, five meta-analyses (MAs) on the value of cardiotocography (CTG) combined with fetal ECG ST interval analysis (CTG+ST) have been published: an updated Cochrane Review (1), one by a European consortium involved in four of the five randomized controlled trials (RCTs) performed on CTG+ST vs. CTG alone (2) (denoted "European MA" in text and tables), one by North American authors (3) ("American MA"), one by a group in Stockholm, Sweden (4) ("Stockholm MA"), and an individual participant data (IPD) MA by the European consortium (5) ("IPD MA"). This monograph focuses on the methodologies employed in the MAs, the clinical outcomes considered, and the execution and quality of each individual MA. New MAs were performed in those events where we found critical differences between the RCTs [see the accompanying Part I review (6) ], and when improper handling of RCT data or errors were found in the five MAs.
Five meta-analyses
Five RCTs on CTG+ST vs. CTG alone were considered for inclusion in the MAs: the "Plymouth RCT" published by Westgate et al. in 1993 (7) , the "Swedish RCT" by Amer-W ahlin et al. in 2001 (8) , the "Finnish RCT" by Ojala et al. in 2006 (9) , the "French RCT" by Vayssi ere et al. in 2007 (10) , and the "Dutch RCT" by Westerhuis et al. in 2010 (11) . After the original articles, revised data from the Swedish and Dutch RCTs were published in 2011 (12) (13) (14) . Metabolic acidosis data from the Finnish RCT have been revised (see below), but not data from the Plymouth and French RCTs.
Statistical analyses
For supplementary statistical calculations, we used the MEDCALC â version 5.00.017 computer software (MedCalc Software, Mariakerke, Belgium). Two-sided statistics were used with a p-value <0.05 considered significant. For performing new MAs, we used the COCHRANE REVIEW MANAGER version 5.2.7 computer software (The Cochrane Collaboration, http://ims.cochrane.org/revman/download). This program assesses heterogeneity with Tau   2 , I
2 and chi-square (Cochrane Q) statistics, where heterogeneity is regarded as substantial if I 2 exceeds 30% or the chi-square test p-value is <0.10. An analysis showing low heterogeneity can be presented with fixed-effect MA and an analysis showing high heterogeneity with random-effect MA; since the result is practically the same with the two models at low heterogeneity, in the text and forest plots we present the results as random-effect MAs.
Types of meta-analysis
The Cochrane, European, American and Stockholm MAs used aggregated data ( Table 1 ). The IPD MA analysed the original raw data from participants in four of the five RCTs. An IPD MA offers numerous statistical and clinical advantages over an aggregate data MA (15) . For example, it increases the power to detect differential treatment effects across individuals in RCTs and allows adjustment for confounding factors in observational studies.
In the Cochrane, European and American MAs, the random-effect and fixed-effect MA models were used as appropriate, after testing for heterogeneity (Table 1) . However, there is no consensus in the literature as to the ideal cut-off point for heterogeneity to be used for each model. For example, Reid (16) recommends the fixedeffect model at an I 2 of ≤25% and the random-effect model at ≥75%, but gives no certain recommendation for values in between. Devane (17) gives a somewhat more precise recommendation: at an I 2 of 0-40%, heterogeneity is not important; 30-60% represents moderate heterogeneity; 50-90% substantial heterogeneity; and 75-100% considerable heterogeneity. Several other interpretations can be found in the literature. The chi-square test has the lowest power to detect heterogeneity and a p < 0.10 indicates heterogeneity according to Devane (17) . While the I 2 index quantifies the degree of heterogeneity in a MA, the chi-square only informs us about the presence or absence of heterogeneity (18) . Devane (17) recommends that in the case of statistical heterogeneity, the reasons for this finding should be investigated and the statistical approach appropriately modified.
In the MAs included in the present review, the cut-offs for I 2 heterogeneity varied from 30% (Cochrane MA) to 40% (American MA) and 50% (European MA) ( Table 1 ). In the American MA, when an I 2 was ≥85%, the authors chose to perform no MA, for example regarding fetal scalp blood sampling (FBS). In the other MAs the random-effect model was then used. The Tau 2 cut-off was set to >0 in the Cochrane and European MAs but was not defined in the American MA; the chi-square p-value was <0.10 in the Cochrane and American MAs but not calculated in the European MA.
Choosing the right model for MA is particularly important for binary outcome variables because the fixed-and random-effect models give different results. When heterogeneity is present, a confidence interval (CI) around the random-effect pooled estimate is wider than the CI around a fixed-effect pooled estimate (19) . Thus, larger series are required in the random-effect model to achieve the same statistical power as in the fixed-effect model (20) . This is illustrated by the calculation of metabolic acidosis in the European MA, showing an I 2 of 33%: the random-effect model showed a non-significant decrease of metabolic acidosis in the CTG+ST group [risk ratio (RR) 0.72, 95% CI 0.43-1.19], but if the pre-defined cut-off for I 2 heterogeneity (50%) is used, the fixed-effect model will show a significant reduction (RR 0.68, 95% CI 0.48-0.97) ( Tables 1 and 6 ).
In summary, fixed-and random-effect models pose different questions. The random-effect model addresses the question "what is the average intervention effect?" whereas the fixed-effects model addresses the question "what is the best estimate of the intervention effect?" (19) . Since the random-effect model estimates the underlying distribution of effects and not a single effect, when the models do not coincide it may not reflect the actual effect in the particular population under study. When heterogeneity is present, the random-effect MA will award more weight to smaller trials than such studies would receive in a fixed-effect MA. Consequently, if the results of smaller trials are consistently different from those of larger ones, which is the case with the Finnish and French RCTs, the direction of the outcomes in the entire MA can be shifted. A random-effect MA as a rule gives a more conservative 95% CI.
Before presenting our evaluation of the individual MAs, it is important to recognize that random-effect analysis is not a solution for the difficulties inherent in translating the results of a MA to the realities of daily clinical practice. The Cochrane Handbook (19) states that the choice between a fixed-effect and a random-effect MA should never be made on the basis of a statistical test for heterogeneity. As will become evident, this recommendation was not uniformly applied to the MAs under consideration.
Inclusion and exclusion of RCTs and their relevant data in the meta-analyses
The Cochrane Review included all five RCTs in its MA and cited the revised versions of the Swedish and Dutch The European MA authors also included all five RCTs in their analysis (Table 2) . However, the Swedish RCT data presented are from the original so-called modified intent-to-treat analysis from 2001 (n = 4966) (8) , not the revised data from the so-called standardized intention-totreat from 2011 (n = 5049) (12) . The European consortium authors aimed to calculate metabolic acidosis with BD ecf data and converted the Finnish BD blood data to BD ecf data to be comparable with the other RCTs, but they included cases with missing blood gases in the denominators when calculating the metabolic acidosis rates (6/733 vs. 4/739 instead of 6/714 vs. 4/722). Thus, the European MA did not contain all relevant data from the five RCTs. In a second sequence of the European MA, "sensitivity analyses" excluded the Plymouth RCT, as it used visual analysis of absolute T/QRS ratios and because biphasic ST interval changes were not yet part of the method (but this is not correct, see below). The American MA included all five RCTs but with the original metabolic acidosis data instead of the revised data from the Swedish trial group (Table 2) . Moreover, the use of BD blood instead of BD ecf to calculate metabolic acidosis in the Finnish RCT was not taken into account (see below). The Stockholm MA also disregarded the fact that the Finnish RCT reported BD blood data. Thus, the American and Stockholm MAs on metabolic acidosis were mixtures of BD ecf and BD blood data ( Table 2 ). The IPD MA aimed to analyse metabolic acidosis with both BD ecf and BD blood calculations of metabolic acidosis and the concepts were not mixed together.
The Stockholm and IPD MAs excluded the Plymouth RCT because of the non-computerized ST analysis methodology and, in the case of the IPD MA, because biphasic ST interval changes were not included in the ST analysis guidelines ( Table 2 ). The latter claim is not entirely correct because negative T wave and ST interval depression with positive T waves were included in the Plymouth RCT management protocol [see Westgate et al., 1993 (7), Table II) ]. In a response to a Letter to the Editor of the American Journal of Obstetrics and Gynecology by Ros en (21), the principal IPD MA author admitted that biphasic ST changes were incorporated in the Plymouth RCT management protocol, and that another reason for not including the Plymouth data was that they had no access to the IPD (22) . The Plymouth RCT authors were contacted but could not provide the required data. This has affected the results of the IPD MA (and the Stockholm MA), since the Plymouth RCT contributed considerable weight, 16.2-17.0%, to the analyses of metabolic acidosis in those MAs that included it (1-3).
The IPD MA authors make an assertion that all RCTs had the same inclusion criteria, making them only "slightly different". However, the French RCT only included women with abnormal CTG in labor with or without meconium-stained amniotic fluid, but excluded normal CTG cases (10) , criteria that in many cases are violations of the ST analysis clinical guidelines and recommendations (23, 24) . This fact alone should have invalidated the French RCT from inclusion not only in the IPD MA but also in the other MAs [for details, see the accompanying Part I review (6) ].
Handling of missing data
Several of the variables evaluated in the MAs were not reported in the original RCTs, and we could not perform post hoc analyses of these variables. The Cochrane Review author contacted the authors of the original reports to provide further data. Representatives from all RCTs except the Plymouth RCT were co-authors of the European MA and IPD MA and could have provided missing data; the American and Stockholm MAs were performed without contributions from authors of the included RCTs.
Fetal scalp blood sampling: discrepancies in the meta-analyses
In all five RCTs, FBS was an adjunct diagnostic tool in both the CTG+ST group and CTG alone group. However, it is unclear why the Swedish RCT data were not available for the IPD MA (Table 3 ). In the Cochrane Review the rates of FBS in the Dutch RCT were tabulated as an outcome variable, but these data were not included in the A new meta-analysis of fetal scalp blood sampling All four MAs that evaluated FBS usage showed significant reductions in the CTG+ST group, ranging from 39 to 51%, but in the Cochrane Review and the IPD MA the data were not complete ( Table 3) . As discussed in the accompanying Part I review (6) and elsewhere in the present review, the French RCT should not be pooled in an MA with the other RCTs because of methodological discrepancies. Our MA including the four other RCTs showed a significant reduction in FBS usage by 36% in the CTG+ST group (RR 0.64, 95% CI 0.47-0.88) ( Figure 1 , Table 4 ).
Operative delivery: discrepancies in the metaanalyses
It is not possible to determine the total cesarean and operative vaginal delivery rates in the Plymouth and French RCTs. Imputed data for the Cochrane Review were provided by the original RCT authors. For reasons that are unclear, data on total operative vaginal delivery rate from the Dutch RCT were not included in the Cochrane Review (Table 3 The European consortium performed a "sensitivity analysis" that excluded the Plymouth RCT, based on its different ST analysis methodology. The sensitivity analysis resulted in a change of result from a total operative delivery RR of 0.94 (95% CI 0.88-0.99) ( Table 3) to 0.95 (95% CI 0.89-1.00). While this change in RR is insignificant, it does result in a CI that includes unity.
The most detailed trial data were presented in the IPD MA by Schuit et al. (5) . We found addition errors in this MA, as pointed out in Tables 3 and 6 . For example, when the numbers of interventions for "fetal distress" and "failure to progress" are added, which, if not otherwise stated, are expected to include the total number of cesarean sections (CS) and instrumental vaginal deliveries, respectively, we found summary discrepancies in all figures of the individual RCTs [for details, see Table 3 
New meta-analyses of operative delivery
As shown in Table 3 , the MAs varied in their analysis of operative delivery rates. All MAs included the French RCT, but for previously stated reasons we excluded the French trial and performed new MAs according to the following hierarchy of analyses and sub-analyses:
• total CS rate, with sub-analysis of CS for fetal distress (FD) among all CSs.
• total instrumental (operative) vaginal delivery rate, with sub-analysis of instrumental delivery for FD among all instrumental vaginal deliveries.
• total operative delivery rate (including CS and operative vaginal deliveries), with sub-analysis of operative delivery for fetal distress (ODFD) among total operative deliveries.
Details of the hierarchy of cases included in these MAs are shown in Table 5 and the results of the MAs are summarized in Table 4 . The forest plot in Figure 2 Table 4 ). The total CS rate was not affected. A minority of operative deliveries were performed for FD, 27-39% in the CTG+ST group and 28-41% in the CTG group (Table 5) ; sub-analyses showed no significant differences in ODFD among either CSs or instrumental vaginal deliveries (Table 4) .
Metabolic acidosis: discrepancies in the meta-analyses
As mentioned above, in the Cochrane, American and Stockholm MAs, metabolic acidosis rates were a mixture of calculations using BD ecf and BD blood (Tables 2 and 6 ). As in the Finnish RCT, it appears that the difference between BD ecf and BD blood metabolic acidosis calculations was not considered, despite important differences in methodology. According to a personal communication between Welin and colleagues (25) and the principal Finnish author, Dr. Ojala, the figures of metabolic acidosis in extracellular fluid were 6/714 (0.8%) in the CTG+ST group and 4/722 (0.6%) in the CTG group (25, 26) . To the best of our knowledge, these data have not been published by the Finnish RCT authors. The Cochrane Review aimed to analyse BD blood metabolic acidosis and included the revised Dutch RCT BD blood data (14) in the MA (Tables 2 and 6 ). The Dutch RCT rates for metabolic acidosis in the CTG+ST group vs. the CTG group, based on those calculated for blood, were 41/2827 (1.45%) vs. 66/2840 (2.32%), respectively; when calculations for metabolic acidosis in extracellular fluid were applied, the subsequent rates were much smaller, 19/2827 (0.67%) vs. 27/2840 (0.95%) (14) . This is a crucial point in MAs because the incidence of BD >12.0 mmol/L may differ by a factor of 4 between BD blood and BD ecf calculations (27, 28) . This difference in definition of an essential RCT outcome variable would be considered a high risk bias according to the Cochrane Handbook for Systematic Reviews of Interventions (19) .
The As discussed above, there were six cases of metabolic acidosis in the CTG+ST analysis group and four in the CTG alone group in the Finnish RCT. Altogether 1472 cases were randomized in the RCT, with blood gas data available in 1436. However, the European consortium MA included all 1472 randomized cases as denominator Figure 2 . Meta-analysis of total operative delivery (sum of cesarean sections and instrumental vaginal deliveries). Data on total cesarean section from the Plymouth randomized controlled trial ) (7) were obtained from the Cochrane Review (1). (Tables 2 and 6 ). Metabolic acidosis data from the original (8) but not from the revised (12) Swedish RCT article were included in the American MA, although the revised data from the Dutch RCT (14) were used. After imputation of missing data in the IPD MA, one additional case of metabolic acidosis using BD ecf occurred in the Swedish RCT data file and six in the French RCT data file, whereas in the Finnish and Dutch RCT files there were no additions ( Table 6 ). The Swedish authors themselves performed an imputation data analysis that resulted in 53 cases (12) , compared with the 54 cases in the IPD MA. This discrepancy remains unexplained.
The French RCT reported the number of cases with BD ecf >12.0 mmol/L. As discussed in the accompanying Part I review (6), as many as 15% of the cases in the RCT had a BD ecf value >12.0 mmol/L and of these, only 15% fulfilled the cord blood sample validation criterion of an arteriovenous pCO 2 gradient >0.5 kPa defined in the study protocol. This confirms that the French RCT included cases at extraordinary high risk for fetal compromise, and indicates a poor quality of cord blood samples.
The IPD MA was the only one to evaluate metabolic acidosis with both BD ecf and BD blood >12.0 mmol/L (Table 6) . BD blood >12.0 mmol/L data were presented from the Finnish and Dutch RCTs but not from the Swedish and French RCTs. It is unclear why this approach was undertaken. The BD blood calculation algorithm was not reported in the IPD MA article (or in the Finnish and Dutch RCTs), but with access to original individual participant pH and pCO 2 data from each trial there is no risk of discrepant post hoc calculations. The concept of an IPD MA is that all individual RCT data shoould be handled as if the MA was a single large multicenter RCT. This is important, since comparing different BD algorithms, the incidence of BD blood >12.0 mmol/L may differ by more than 150% (2.5 times) (28) . Different algorithms in the Finnish RCT and the IPD MA to calculate BD blood might explain why the original 17 cases of BD blood >12.0 mmol/L in the Finnish RCT increased to 23 when included in the IPD MA. Such large discrepancies between blood gas analyzers are clinically important: at low and moderately high BD blood values the inter-analyzer difference might be 3-4 mmol/L and at high values up to 8-9 mmol/L (28).
New meta-analysis of neonatal metabolic acidosis
Our judgement is that the relevant rates of metabolic acidosis in extracellular fluid should be represented by data published in the original Plymouth and French RCT articles (7, 10) , the Swedish and Dutch revised data articles (12, 14) , and data presented by Welin and coworkers after communication with the principal Finnish RCT author (25) . Figure 3 shows a forest plot with inclusion of these data from the Plymouth, Swedish, Finnish and Dutch RCTs: fetal surveillance with CTG+ST analysis resulted in a significant 39% reduction in metabolic acidosis compared with surveillance with CTG alone (RR 0.61, 95% CI 0.41-0.91).
Admission to the neonatal intensive care unit: discrepancies in the meta-analyses Admissions to the neonatal intensive care unit (Table 6) were reported in all five RCTs. Fewer cases were included (12, 14) , while the Plymouth data are from the original article (7). The European consortium MA authors inexplicably excluded the Finnish RCT mortality data. However, in the IPD MA, also performed by the European consortium, the Finnish data were included. In the IPD MA the Swedish RCT was represented by mortality corrected for lethal malformations but the Dutch RCT was represented by uncorrected mortality figures. These discrepancies raise concern about the interpretation of data on perinatal mortality.
Conclusions
To perform an MA, the included RCTs should address the same research question, be of comparable quality regarding selection bias, attrition rates and confounding variables, and include comparable populations (16) . As discussed in the accompanying Part I review (6), there were considerable discrepancies in these aspects among the five RCTs. Furthermore, numerous errors appear to have occurred in the MAs, either created de novo in handling of the original or imputed data or through a failure to recognize some critical differences in data presentations in the RCTs. Metabolic acidosis, an essential perinatal outcome parameter, was presented as a mixture of BD blood and BD ecf data in the Cochrane, American and Stockholm MAs.
None of the five MAs contained complete and relevant data from all of the five RCTs. The decisions of the authors of the various MAs to include some or all of the RCT data in their analyses differed considerably. While the RCTs included in the MAs clearly differed in inclusion criteria, a question central to any MA is whether the system being studied was used as intended and was labelled by its manufacturer. With this in mind, we are of the opinion that the French RCT should have been excluded, since initiating ST monitoring in fetuses with clearly abnormal CTGs is contrary to existing guidelines. Conversely, the exclusion of the Plymouth RCT on the basis of its older technology would appear unwarranted, as this RCT, using manual rather than automated ST analysis, would to an even greater extent have challenged the ability of the CTG+ST analysis system to improve perinatal outcomes.
It is unfortunate that the IPD MA, with its potential clinical and statistical advantages over the aggregate MAs, was found to have several errors. This could have led to unintended bias in both the experimental and control groups. For the outcomes of FBS, operative delivery, ODFD, neonatal metabolic acidosis and neonatal Sarnat & Sarnat encephalopathy stage ≥2, we have performed new MAs. These showed not only, like the previous MAs, a significant reduction in FBS usage in the CTG+ST group (reduction of 36%), but also significant reductions in total operative delivery rate (reduction of 7%) and in neonatal metabolic acidosis rate (reduction of 39%). The results of the ongoing multicenter RCT in the United States (http://clinicaltrials.gov/ct2/show/NCT01131260) are some months away. Certainly the contribution of the USA data will help to determine whether the addition of ST analysis to conventional CTG results in improved perinatal outcomes.
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